Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-21
DOI
10.1038/s41598-019-45178-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy
- (2018) Zhi-Ming Ding et al. Frontiers in Pharmacology
- Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis
- (2018) Pegah Golabi et al. MEDICINE
- Bile acids and their effects on diabetes
- (2018) Cynthia Rajani et al. Frontiers of Medicine
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Pathology of non-alcoholic fatty liver disease
- (2017) Pierre Bedossa LIVER INTERNATIONAL
- Induction of Steatohepatitis (NASH) with Insulin Resistance in Wild-type B6 Mice by a Western-type Diet Containing Soybean Oil and Cholesterol
- (2017) Janin Henkel et al. MOLECULAR MEDICINE
- Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
- (2017) Wei Jia et al. Nature Reviews Gastroenterology & Hepatology
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
- (2017) Pedro M Rodrigues et al. Cell Death & Disease
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease and dyslipidemia: An update
- (2016) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
- (2016) Fahrettin Haczeyni et al. Obesity
- Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage
- (2015) Liangpeng Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice
- (2015) Tamiris Lima Rachid et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects
- (2014) Rémy Hanf et al. Diabetes & Vascular Disease Research
- Overactivation of Intestinal SREBP2 in Mice Increases Serum Cholesterol
- (2014) Ke Ma et al. PLoS One
- IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients
- (2014) Chiara Rosso WORLD JOURNAL OF GASTROENTEROLOGY
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
- (2014) Hannele Yki-Järvinen Lancet Diabetes & Endocrinology
- Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
- (2013) Jason R. Clapper et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Bile acid receptors in non-alcoholic fatty liver disease
- (2013) Yuanyuan Li et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Immune and inflammatory pathways in NASH
- (2013) Michal Ganz et al. Hepatology International
- Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
- (2013) Rachel H. McMahan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation
- (2013) Barbara Renga et al. PLoS One
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
- (2012) Geoffrey Porez et al. JOURNAL OF LIPID RESEARCH
- The PPARβ/δ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1α-Lipin 1-PPARα Pathway Leading to Increased Fatty Acid Oxidation
- (2011) Emma Barroso et al. ENDOCRINOLOGY
- PPARs: diverse regulators in energy metabolism and metabolic diseases
- (2010) Yong-Xu Wang CELL RESEARCH
- Mouse models of the metabolic syndrome
- (2010) A. J. Kennedy et al. Disease Models & Mechanisms
- The regulation of inflammation by galectin-3
- (2009) Neil C. Henderson et al. IMMUNOLOGICAL REVIEWS
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells
- (2009) Eduardo L.M. Guimarães et al. JOURNAL OF HEPATOLOGY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
- (2009) Maryam Rakhshandehroo et al. PLoS One
- Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
- (2009) Stefano Fiorucci et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- (2008) Justin I. Odegaard et al. Cell Metabolism
- Human health risk assessment for peroxisome proliferators: More than 30 years of research
- (2008) Marco Fidaleo EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More